期刊文献+

中西医结合治疗Ⅲc期复发性卵巢癌的临床研究

原文传递
导出
摘要 目的探讨中西医结合治疗Ⅲc期复发性卵巢癌的临床效果。方法选择我院收治的68例Ⅲc期复发性卵巢癌患者为本次研究的对象,随机将68例患者分为A、B两组,每组为34例。其中,A组采取单纯西医治疗方法,B组采取中西医结合治疗方法,对比两组患者的治疗效果。结果 B组相较于A组,总体死亡率明显更低,长期(3年后)治疗存活率明显更高,组间差异显著,具有可比性(P<0.05)。结论在Ⅲc期复发性卵巢癌患者的治疗过程中应用中西医结合方法,具有良好的临床治疗效果,值得大力推广和应用。
作者 李彦丽
出处 《首都食品与医药》 2018年第11期15-15,共1页 Capital Food Medicine
  • 相关文献

参考文献3

二级参考文献24

  • 1张娜.中西医结合治疗复发性尿路感染的临床分析[J]中国药物经济学,2013(02).
  • 2Eisenhauer EA,Therasse P,Bogaerts J, et al. New response e- valuation criteria in solid tumours: revised RECIST guideline (version 1.1) [J].EurJ Cancer,2009,45(2):228-247.
  • 3Trotti A, Colevas AD,Setser A,et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treat- ment[J]. Semin Radiat Oncol,2003, 13(3): 176-181.
  • 4Matsumoto K,Katsumata N,Shibata T, et al. Phase Ⅱ trial of oral etoposide plus intravenous irinotecan in patients with plati- num-resistant and taxane-pretreated ovarian cancer (JCOG0503) [J]. Gynecol Oncol, 2015,136(2) : 218-223.
  • 5Tomao F, Tomao S,Benedetti Panici P, et al. Combination of bev- acizumab and chemotherapy for platinum-resistant recurrent ovarian cancer: some observations about the AURELIA trial[J]. J Clin On- coi,2014,32(31) :3580.
  • 6Safra T,Asna N,Veizman A, et al. The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum- resistant and platinum-sensitive recurrent epithelial ovarian cancer pa- tients[J]. Anticanccr Drugs,2014,25(3) :340-345.
  • 7Vergote I, Schilder RJ,Pippitt CH Jr, et al. A phase lb study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or par- tially platinum-sensitive ovarian cancer[J]. Gynecol Oncol, 2014, 135(1) :25-33.
  • 8Hong SH, Lee S,Kim HG,et al. Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary perito- neal cancer by the Korean Cancer Study Group (KCSG)_KCSG GYI0-10[J]. Gynecol Oneoi,2015,136(2) :212-217.
  • 9Musella A, Marehetti C,Palaia I,et al. Secondary cytoreduction in platinum-resistant recurrent ovarian cancer: a single-institu-tion experience[J]. Ann Surg Oneo1,2015,22(13):4211-4216.
  • 10Stasenko M, Plegue M, Sciallis AP, et al. Clinical response to antiestrogen therapy in platinum-resistant ovarian cancer pa- tients and the role of tumor estrogen receptor expression status [J]. Int J Gynecol Cancer,2015,25(2) :222-228.

共引文献59

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部